SLCTR/2021/003已完成4 期
The third, INTEnsive care bundle with blood pressure Reduction in Acute Cerebral haemorrhage Trial
适应症
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Age >= 18 (both male and female)
- •Acute stroke syndrome that is due to presumed spontaneous ICH, confirmed by clinical history and a CT scan within 6 hours of stroke onset without/without contrast, and if an CT angiogram is also undertaken as part of routine care.
- •Presentation to hospital within 6 hours of stroke onset
排除标准
- •Definite evidence that the ICH is secondary to a structural abnormality in the brain (eg an AVM, intracranial aneurysm, tumour, trauma, or previous cerebral infarction) or previous thrombolysis.
- •A high likelihood that the patient will not adhere to the study treatment and follow-up regimen. In each case, the decision about the patient’s eligibility will be based on the attending clinician’s interpretation of the above eligibility criteria
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of AgeCoronavirus Disease 2019EUCTR2021-000281-15-Outside-EU/EEAModernaTX, Inc.
进行中（未招募）
不适用
Study to evaluate the efficacy and safety of an antibiotic cream admistered twice daily for 5 days in patients, including children, with an skin infection called impetigoMedDRA version: 14.1Level: PTClassification code 10021531Term: ImpetigoSystem Organ Class: 10021881 - Infections and infestationsImpetigoEUCTR2011-003032-31-DEFerrer Internacional, S.A.465
已完成
不适用
A phase III, randomised, multicentre, dose escalation, efficacy and safety study examining the effects of treatment with peginterferon alfa-2a with Child's A or B cirrhosis in Chronic Hepatitis C virus infectioISRCTN88008850Southampton University Hospitals NHS Trust (UK)100
招募中
1 期
A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherapy compared with placebo in subjects with moderate-to-severe atopic hand eczema who are candidates for systemic therapy (ADHAND)Atopic dermatitis and moderate-to severe atopic hand eczemaMedDRA version: 21.1Level: LLTClassification code: 10003639Term: Atopic dermatitis Class: 10040785MedDRA version: 21.1Level: LLTClassification code: 10003641Term: Atopic eczema Class: 10040785CTIS2022-502653-34-01EO PHARMA A/S402
未知
不适用
A PHASE 3, 40-WEEK, ACTIVE-CONTROLLED, DOUBLE-BLIND EXTENSION STUDY OF PRELADENANT IN SUBJECTS WITH MODERATE TO SEVERE PARKINSON´S DISEASE (PHASE 3, PROTOCOL N° P06153)PER-038-11SCHERING PLOUGH RESEARCH INSTITUTE,